Could (Nasdaq: CRDL) Earn Breakout Buzz As Its Phase II ARCHER Study Aims For Full Enrollment 6 Months Early?
It's absolutely imperative to keep a hawk-eyed focus on any company delving into the fight against inflammation and fibrosis in heart diseases while pioneering therapies.
Why? Because heart diseases, including Pericarditis, Myocarditis, and Heart Failure, are vicious adversaries, relentlessly wreaking havoc on countless lives.
Understanding the ruthless role that inflammation and fibrosis play in these conditions is not just a luxury; it's a dire necessity to combat this silent assassin effectively.
These heart conditions are insidious, sharing malevolent pathological mechanisms rooted in inflammation and fibrosis.
A company laser-focused on cracking this code has the potential to unleash revolutionary treatments, shifting the balance of power in our favor.
Oh yeah... Don't get me started on the Inflammasome – that's the enemy within, a relentless adversary in the realm of the immune system.
Targeting it could be the game-changer, not only for heart diseases but for an array of inflammatory afflictions.
And right now, one company flying below Wall Street's radar may hold the keys to a brighter, healthier future in the relentless battle against heart diseases.
Add in that Barchart is reporting this breakout idea to have 10+ triggered technical indicators and that this profile closed above 3 key technical lines Wednesday, and you'll understand why you need to drop everything and pull up:
*Cardiol Therapeutics Inc. (CRDL)*
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
The Company’s lead small molecule drug candidate, CardiolRx™ (cann-a-bidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
And right now CRDL has several must-know potential catalysts that could provide it with a near term breakout spark. Check them out:
No. 1 - Technical Indicators Triggered Bullish (10+ In All!)
No. 2 - CRDL Plans To Reach Crucial Milestone Up To 6 Months Early
No. 3 - Analysts Provide Positive Sentiment With Strong Price Targets
No. 4 - Could Key Chart Support Be Growing At Multiple Levels?
But more on those in a second...
Cardiol's Immediate Focus
The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.
Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States; following an initial episode, 15 – 30% of patients experience a recurrence.
Pericarditis refers to inflammation of the membrane or sac that surrounds the heart (the pericardium) that is most frequently triggered from a viral infection. Recurrent pericarditis is the most common complication following an initial acute episode of pericarditis, and patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Infrequent but life-threatening complications associated with pericarditis include a large accumulation of pericardial fluid, scarring, and constriction of the heart which may limit heart function. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.
Cardiol is conducting a Phase II open-label pilot study (MAvERIC-Pilot) designed to evaluate the tolerability, safety, and efficacy of their lead investigational drug, CardiolRx™, in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™.
Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is an acute inflammatory condition of the heart muscle (myocardium) characterized by chest pain, impaired cardiac function, atrial and ventricular arrhythmias, and conduction disturbances. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Although viral infection is the most common cause of myocarditis, the condition can also result from bacterial infection, commonly used drugs and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors.
CardiolRx™ is currently being evaluated in a Phase II multi-national study (ARCHER) to evaluate its safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. ARCHER is expected to enroll 100 patients at major cardiac centers in North America, Europe, Latin America, and Israel.
Heart failure affects more than 64 million people globally and associated healthcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is a chronic, progressive syndrome in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. People with heart failure suffer from shortness of breath, rapid heart rate, edema, reduced exercise capacity, often struggle with simple daily activities, and are frequently hospitalized. For many, these symptoms significantly reduce their quality of life. Known causes of heart failure include ischemic heart disease and myocardial infarction (heart attack), hypertension, valvular heart disease, inflammatory diseases of the heart such as myocarditis and cardiomyopathies, anti-cancer therapies, and inherited metabolic diseases.
CRD-38 is their novel proprietary drug formulation designed to deliver cann-a-bidiol by subcutaneous administration. They are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care.
Inflammasomes are large, intracellular, multiprotein, sensor complexes which under normal conditions are essential to innate immunity and maintaining homeostasis. The NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is the most extensively studied. Aberrant activation of inflammatory pathways, including the NLRP3 inflammasome, occurs under various conditions such as obesity, hypertension, diabetes, and autoimmunity, or in response to a trigger (e.g., viral infection). This activation contributes to the release of cytokines (IL-1β; IL-6; IL-18) and mechanisms (pyroptosis; endothelial dysfunction) which lead to a cycle of inflammation and fibrotic responses.
These responses are associated with contributing to the pathogenesis and progression of heart diseases including pericarditis, myocarditis, and heart failure. The exact mechanism by which their investigational drugs inhibit inflammation and fibrosis is not fully elucidated; however, their research and that of others suggests that the active pharmaceutical ingredient in CardiolRx™ and CRD-38 attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome. By targeting inflammatory signaling pathways, their approach has therapeutic potential to heal the heart.